Acrivon Therapeutics ACRV

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.04 (+0.73%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of Acrivon Therapeutics (ACRV)
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $5.54

  • Market Cap

    $172.50 Million

  • Price-Earnings Ratio

    -2.08

  • Total Outstanding Shares

    31.14 Million Shares

  • Total Employees

    61

  • Dividend

    No dividend

  • IPO Date

    November 15, 2022

  • SIC Description

    Pharmaceutical Preparations

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Headquarters

    480 arsenal way, suite 100, Watertown, MA, 02472

  • Homepage

    https://www.acrivon.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow, Continuing$13.34 Million
Net Cash Flow From Operating Activities, Continuing$-60.67 Million
Net Cash Flow From Investing Activities, Continuing$-45.65 Million
Net Cash Flow From Investing Activities$-45.65 Million
Net Cash Flow From Operating Activities$-60.67 Million
Net Cash Flow From Financing Activities$119.66 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Other Operating Expenses$24.46 Million
Net Income/Loss$-76.98 Million
Revenues$0
Basic Average Shares$32.38 Million
Income/Loss From Continuing Operations After Tax$-76.98 Million
Net Income/Loss Attributable To Noncontrolling Interest$0

Comprehensive Income

October 1, 2023 to September 30, 2024
MetricValue
Other Comprehensive Income/Loss$1.08 Million
Comprehensive Income/Loss$-75.89 Million
Comprehensive Income/Loss Attributable To Parent$-75.89 Million
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Other Current Liabilities$13.31 Million
Fixed Assets$4.67 Million
Other Non-current Assets$21.03 Million
Equity Attributable To Parent$196.89 Million
Liabilities$17.79 Million
Current Assets$188.98 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about ACRV from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    â“’ 2025 Financhle. All Rights Reserved.